Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02421367 · ClinicalTrials.gov registry record · Phase 1
Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT02421367 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 140 participants.
The verdict
NCT02421367, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the safety and immunogenicity and antibody persistence of the candidate dengue vaccine.
Interventions
- BIOLOGICAL TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2015-08 |
| Est. Completion | 2018-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02421367
The ClinicalTrials.gov registry entry for NCT02421367 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution. is the first listed.
NCT02421367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02421367 about?
NCT02421367 is a clinical study titled "Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults". This study is being conducted to evaluate the safety and immunogenicity and antibody persistence of the candidate dengue vaccine.
What is the current status of trial NCT02421367?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2015-08. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02421367?
The interventions under investigation include: TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution. (BIOLOGICAL).
Who is sponsoring clinical trial NCT02421367?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.